San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Headlands Research is raising $9,285,302.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Mark Blumling played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Headlands Research

Headlands Research is a leading globally integrated clinical trial site organization with the mission of dramatically improving the clinical trials process. Headlands is providing the highest level of clinical trial quality through Integrating cutting edge technology and high-quality support services, an exceptional platform of next generation sites, and Significantly expanding trial participant outreach and participation.

To learn more about Headlands Research, visit http://www.headlandsresearch.com/

Contact:
Mark Blumling, President and Chief Executive Officer
727-543-4604
mark.blumling@headlandsresearch.com
https://www.linkedin.com/in/markblumling/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved